Abstract
Objective: To conduct an economic analysis on the use of carboplatin versus cisplatin over multiple courses in patients with lung [nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC)] or ovarian cancer.
Design: This 1-year study was a prospective, multicentre, cost-minimisation evaluation. Direct medical resource utilisation and costs associated with carboplatin and cisplatin administration over 3 to 6 courses of treatment were measured and compared. The perspective of this evaluation was that of the payer.
Setting: A convenience sample of 16 sites representing a mix of cancer centres, outpatient clinics, medical centres and managed-care sites in a general practice oncology setting participated.
Patients and interventions: Patients were included in this study if they were newly diagnosed with NSCLC, SCLC or ovarian cancer, had not received prior chemotherapy, received either carboplatin or cisplatin as their treatment (additional chemotherapy agents were allowed), and received at least 3 courses of carboplatin or cisplatin therapy up to a maximum of 6 courses. Patients receiving more than 6 courses of therapy were included in this study, but data collection on those patients stopped after the sixth course.
Individuals involved with data collection at all sites were trained via on-site and/or teleconference training. Site visits were made to assure reliability of at least 0.80. Data were collected and compiled via a fax transmission process that scans directly through optical mark and character recognition into a computer database. Outcome measures included costs of: medications, emergency room visits, physician/clinic/laboratory visits, home healthcare visits, transfusions, special procedures, consultations, hospitalisations and other/miscellaneous costs.
Main outcome measures and results: Of 220 patients, 164 met the study criteria (response rate = 74.2%) with 95 patients in the carboplatin group (NSCLC = 45 SCLC = 18, ovarian = 32) and 69 in the cisplatin group (NSCLC = 36, SCLC = 21, ovarian = 12). The average number of courses were: NSCLC = 4.3 and 4.2, SCLC = 4.3 and 4.8, and ovarian = 4.7 and 5.1, respectively, for carboplatin and cisplatin. The total costs (treatment and toxicity) associated with the use of carboplatin were higher in NSCLC, similar in SCLC but lower in ovarian cancer.
Conclusions: These results indicate that overall treatment costs may vary depending on cancer type, even when the same drugs are used. The total costs (treatment plus toxicity costs) associated with the use of carboplatin were higher than those of cisplatin in patients with NSCLC, similar in SCLC, but lower in ovarian cancer.
Similar content being viewed by others
References
Cancer facts & figures: 1998. Atlanta (GA): American Cancer Society, Inc., 1998
Goodyear MDE, Fraumeni MA. Incoporating quality of life assessment into clinical cancer trials. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. New York (NY): Lippincott-Raven Publishers, 1996: 1003–14
Bungay KM, Boyer JG, Steinwald AB, et al. Health-related quality of life: an overview. In: Bootman JL, Townsend RJ, McGhan WF, editors. Principles of pharmacoeconomics. 2nd ed. Cincinnati (OH):Harvey Whitney Books Company, 1996: 128–48
Physicians’ desk reference. 53rd ed. Montvale (NJ): Medical Economics Company Inc., 1999: 789–96
5. 1998 guide to cancer chemotherapeutic regimens. Pharm Pract News 1998; Autumn Suppl.: 26–32
Alberts DG, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a Phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10: 706–17
Anderson H, Wagstaff J, Crowther D, et al. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced ovarian cancer. Eur J Cancer Clin Oncol 1988; 24: 1471–9
Bruzzone M, Chiara S, Oliva C, et al. Randomized study comparing carboplatin (CBDCA) + adriamycin + cyclophosphamide (CAC) versus cisplatin (CDDP) + adriamycin + cyclophosphamide (PAC) in ovarian cancer FIGO stage IIIIV [abstract]. Ann Oncol 1990; 1 Suppl. 1: 14
Alberts D. Cisplatin versus carboplatin in advanced ovarian cancer: an economic analysis. Pharmacol Ther 1994; Jul: 1–6
Calvert AH, Urie J. The costs of carboplatin. Semin Oncol 1991; 18 Suppl. 2: 28–31
George MJ, Lenfant-Pejovic MH, Lhomme C, et al. Comparative costs of two chemotherapy regimens: cyclophosphamide (C) and cisplatin (P) vs C and carboplatin (JM8) in advanced ovarian carcinoma (OC) [abstract 598]. Proc Am Soc Clin Oncol 1989; 8: 154
Medicare Medical Claims Database (MEDPAR). Health care financing administration. Washington, DC: MEDPAR, 1990
Physicians’ fee reference 1996. 12th ed. West Allis (WI): Wasserman Medical Publishers, Ltd., 1996
The 1996 Medicare fee schedule: locality 18. Dallas (TX): Medicare, 1996
Khan ZM, Rascati KL, Koeller JM, et al. The use of FAX technology in collecting health outcomes data. Am J Health Syst Pharm. In press
Cardinale V. 1996 drug topics redbook. Montvale (NJ):Medical Economics Company Inc., 1996
Tighe M, Goodman S. Carboplatin versus cisplatin. Lancet 1988; II: 1372–3
Comparison of treatment measures related to the administration of carboplatin and cisplatin. Resto (VA): Center for Economic Studies in Medicine, 1989
SAS Institute Inc. SAS user’s guide: statistics. 5th ed. Cary (NC): SAS Institute, Inc., 1990
Faber LP. Lung cancer. In: Holleb AI, Fink DJ, Murphy GP, editors. American Cancer Society textbook of clinical oncology. Atlanta (GA): American Cancer Society, Inc, 1991: 194–212
Gusberg SB, Runowicz CD. Gynecologic cancers. In: Holleb AI, Fink DJ, Murphy GP, editors. American Cancer Society textbook of clinical oncology. Atlanta (GA): American Cancer Society, Inc, 1991: 481–97
Casciato DA, Lowitz BB. Manual of clinical oncology. 2nd ed. Boston (MA): Little, Brown and Company, 1988
Rees GJ. Cost-effectiveness in oncology. Lancet 1985; II (8469–70): 1405–7
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khan, Z.M., Rascati, K.L. & Koeller, J.M. Economic Analysis of Carboplatin Versus Cisplatin in Lung and Ovarian Cancer. Pharmacoeconomics 16, 43–57 (1999). https://doi.org/10.2165/00019053-199916010-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199916010-00005